Short radiation, chemo, and immunotherapy for advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of short-course radiation, chemotherapy (CAPOX), and an immunotherapy drug (ivonescimab) for people with locally advanced rectal cancer. It aims to see if this approach can shrink tumors before surgery, especially for high-risk cases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that has not spread to other parts of the body
- Your tumor is within 10 cm of the anal opening
- Your MRI shows at least one high-risk feature, like a tumor deeper than T2, blood vessel involvement, or suspicious lymph nodes
- You have good organ function (kidneys, liver, etc.) as determined by standard tests
- Your cancer is not MSI-H or dMMR (a specific genetic feature that usually responds well to immunotherapy alone)
- You have not had pelvic radiation or immunotherapy before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This trial tests a new treatment approach for locally advanced rectal cancer that is pMMR/MSS. It combines a short course of radiation before surgery with a drug called ivonescimab and chemotherapy, aiming to improve outcomes.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard short-course radiation and chemotherapy improves outcomes in people with a common type of locally advanced rectal cancer (pMMR/MSS). It is for those with stage II or III cancer that has at least one high-risk feature and is within 12 cm of the anal verge.
This trial tests a combination of short-course radiation, chemotherapy (CAPOX), and an immunotherapy drug (PD-1 inhibitor) for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can improve outcomes before surgery.
This study tests a combination of radiation therapy, chemotherapy drugs (capecitabine and oxaliplatin), and two types of immunotherapy (a PD-1 blocker and IL-2) for locally advanced rectal cancer. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.